Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OmniAb Inc. (OABI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: OABI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $8.25
1 Year Target Price $8.25
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.87% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 207.97M USD | Price to earnings Ratio - | 1Y Target Price 8.25 |
Price to earnings Ratio - | 1Y Target Price 8.25 | ||
Volume (30-day avg) 8 | Beta 0.65 | 52 Weeks Range 1.22 - 4.96 | Updated Date 06/29/2025 |
52 Weeks Range 1.22 - 4.96 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -229.11% | Operating Margin (TTM) -453.64% |
Management Effectiveness
Return on Assets (TTM) -13.18% | Return on Equity (TTM) -21.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 186854071 | Price to Sales(TTM) 7.78 |
Enterprise Value 186854071 | Price to Sales(TTM) 7.78 | ||
Enterprise Value to Revenue 6.99 | Enterprise Value to EBITDA -10.62 | Shares Outstanding 122335000 | Shares Floating 92829276 |
Shares Outstanding 122335000 | Shares Floating 92829276 | ||
Percent Insiders 6.12 | Percent Institutions 67.98 |
Analyst Ratings
Rating 3 | Target Price 8.25 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OmniAb Inc.
Company Overview
History and Background
OmniAb, Inc. (formerly Ligand Sciences 2.0 HoldCo, Inc.) was founded to provide its partners access to diverse antibody repertoires and technologies to discover next-generation therapeutics. The company has evolved from a provider of antibody discovery technologies to a leader in therapeutic antibody discovery and development.
Core Business Areas
- Antibody Discovery Technology: Offers a suite of transgenic animals, microfluidics, and artificial intelligence-based tools for antibody discovery. It licences its antibody discovery platforms to biopharmaceutical companies for their internal R&D programs.
- Therapeutic Antibody Development: Develops its own pipeline of therapeutic antibody candidates, focusing on oncology and autoimmune diseases. This involves partnering with other companies to co-develop and commercialize therapeutic antibodies.
Leadership and Structure
Matt Foehr is the CEO. The company operates with a management team overseeing its various business units, research, and development efforts. It also has a board of directors to govern the company.
Top Products and Market Share
Key Offerings
- OmniAb Platforms (OmniRat, OmniMouse, OmniFlic, OmniChicken, OmniSeq): These are transgenic animal platforms used for antibody discovery. Market share information is not publicly available for each specific platform; however, revenues derived from licensing and milestones associated with these platforms can be inferred from financial statements. Competitors in antibody discovery include Ablexis (AlivaMice), Harbour BioMed (Harbour Mice), and Regeneron (VelocImmune).
- Therapeutic Antibody Pipeline (Various Preclinical/Clinical Candidates): OmniAb is developing a portfolio of therapeutic antibody candidates focused on diverse diseases. Market share will only be applicable upon successful approval and commercialization of these candidates. Competitors depend on the specific target of each antibody but broadly include major pharmaceutical companies such as Roche, Novartis, and AbbVie, as well as biotech companies developing antibody-based therapies.
Market Dynamics
Industry Overview
The antibody discovery and development market is experiencing significant growth due to the increasing demand for antibody-based therapies for various diseases, including cancer, autoimmune disorders, and infectious diseases. The industry is characterized by intense competition and rapid technological advancements.
Positioning
OmniAb is positioned as a technology provider and a therapeutic developer. Its competitive advantage lies in its diverse suite of transgenic animal platforms and integrated antibody discovery process.
Total Addressable Market (TAM)
The global antibody therapeutics market is projected to reach hundreds of billions of dollars. OmniAb is positioned to capture a share of this TAM through licensing its technology and developing its own therapeutic antibodies.
Upturn SWOT Analysis
Strengths
- Diverse antibody discovery platforms
- Integrated antibody discovery process
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on partners for clinical development and commercialization
- Pipeline is still early stage
Opportunities
- Growing demand for antibody-based therapies
- Expansion of platform applications
- Strategic partnerships and collaborations
- Acquisition of complementary technologies
Threats
- Competition from other antibody discovery companies
- Clinical trial failures
- Regulatory hurdles
- Economic downturns affecting biotech investment
Competitors and Market Share
Key Competitors
- Regeneron Pharmaceuticals Inc. (REGN)
- Harbour BioMed (2142.HK)
- Ligand Pharmaceuticals Incorporated (LGND)
Competitive Landscape
OmniAb's competitive advantage lies in its integrated technology platforms that provide a comprehensive solution for antibody discovery and development. Disadvantages stem from their reliance on partners and their pipeline still being in early stages.
Major Acquisitions
Octane Biotech
- Year: 2022
- Acquisition Price (USD millions): 85
- Strategic Rationale: Acquisition of Octane Biotech expanded OmniAb's technology capabilities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on financial performance data; refer to financial statements.
Future Projections: Future projections are dependent on analyst estimates; refer to analyst reports and financial news sources.
Recent Initiatives: Recent strategic initiatives include expanding platform applications, partnering with biopharmaceutical companies, and advancing its therapeutic antibody pipeline.
Summary
OmniAb is a growing antibody discovery company with robust platform technology. The success hinges on its partnerships and progressing its therapeutic pipeline. The reliance on other companies is a risk to watch out for. The company is in a competitive market but has some key advantages, such as integrated platforms and a wide range of targets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2022-11-02 | President, CEO & Director Mr. Matthew W. Foehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://www.omniab.com |
Full time employees 114 | Website https://www.omniab.com | ||
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.